Finance

Lists
Q2 2026 earnings • released • EPS miss -7.54% • Revenue beat +8.43%
See results
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$256.56
-0.04%
(-0.090) 1D
$256.56
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JAZZ...
Open
$257.49
High
$258.38
Low
$254.69
Mkt. cap
16.65B
Avg. vol.
800.56K
Volume
970.71K
P/E ratio
17.54
52-wk high
$265.04
52-wk low
$109.87
EPS
$14.63
Beta
0.32
Shares outstanding
64.92M
No. of employees
3K
Open
$257.49
High
$258.38
Low
$254.69
Mkt. cap
16.65B
Avg. vol.
800.56K
Volume
970.71K
P/E ratio
17.54
52-wk high
$265.04
52-wk low
$109.87
EPS
$14.63
Beta
0.32
Shares outstanding
64.92M
No. of employees
3K
News stories
From sources across the web
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com
Analyst ratings
Based on 17 analysts giving stock ratings to JAZZ in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for JAZZ in the last 3 months.
Highest
Current $256.56
$315.00 (+22.78%)
Average
$283.82 (+10.63%)
Lowest
$229.00 (-10.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$300.00
+16.9%
08/05/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$307.00
+19.7%
08/03/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$280.00
+9.1%
08/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$300.00
+16.9%
08/03/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$275.00
+7.2%
08/04/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$276.00
+7.6%
08/04/2026
Ashwani Verma
UBS
Buy
Reiterated
$315.00
+22.8%
08/04/2026
Gregory Renza
Truist Financial
Buy
Maintained
$264.00
+2.9%
08/04/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$310.00
+20.8%
08/04/2026
Ami Fadia
Needham
Buy
Reiterated
$292.00
+13.8%
08/04/2026
David Hoang
Deutsche Bank
Buy
Reiterated
$287.00
+11.9%
08/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$280.00
+9.1%
08/04/2026
Etzer Darout
Barclays
Buy
Maintained
$270.00
+5.2%
08/04/2026
Joseph Thome
TD Cowen
Buy
Reiterated
$300.00
+16.9%
08/04/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$258.00
+0.6%
07/31/2026
Unknown Analyst
Jefferies
Buy
Maintained
$282.00
+9.9%
07/13/2026
Joon Lee
Truist Financial
Buy
Initiated
$256.00
-0.2%
06/09/2026
Jeffrey Walch
Bernstein
Hold
Reiterated
$229.00
-10.7%
06/08/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$265.00
+3.3%
05/20/2026
Tiago Fauth
Raymond James
Buy
Maintained
$239.00
-6.8%
05/06/2026
Unknown Analyst
Raymond James
Buy
Maintained
$239.00
-6.8%
05/06/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$5.71 / $6.18
-7.54%miss
Revenue / Est. (USD)
1.21B / 1.11B
+8.43%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.13B
1.20B
1.07B
1.21B
Cost of goods sold
128.88M
112.92M
96.60M
116.40M
Cost of revenue
128.88M
112.92M
96.60M
116.40M
Research and development expenses
198.20M
172.66M
196.00M
207.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
379.15M
418.46M
352.70M
389.20M
Operating expense
745.72M
760.86M
721.00M
766.70M
Total operating expenses
874.60M
873.79M
817.60M
883.10M
Operating income
251.51M
324.14M
251.30M
325.20M
Other non operating income
-
-
122.80M
-
EBT including unusual items
8.99M
208.41M
299.20M
210.90M
EBT excluding unusual items
202.99M
278.02M
336.70M
287.90M
Income tax expense
-242.42M
4.96M
6.10M
18.10M
Effective tax rate
-2,697.20%
2.38%
2.04%
8.58%
Other operating expenses
-
-
-
-
Net income
251.41M
203.45M
293.10M
192.80M
Net profit margin
22.33%
16.98%
27.42%
15.96%
Earnings per share
8.13
6.64
6.34
5.71
Interest and investment income
18.60M
20.50M
23.40M
25.30M
Interest expense
-67.18M
-65.91M
-63.30M
-62.40M
Net interest expenses
-48.58M
-45.41M
-39.90M
-37.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
429.76M
503.31M
432.70M
504.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps